

Supplementary Table 2. Use of hormone therapy and risk of colorectal cancer. Sensitivity analysis where CRC cases diagnosed in 2004 were censored.

	HT use	PY	CRC cases	RR (95% CI)
Status	Non-use	2,126,753	2,580	Reference
	Current use	320,202	357	0.83 (0.74-0.93)
	Past use	203,759	332	1.10 (0.98-1.24)
	Ever use	523,961	689	0.94 (0.86-1.03)
HRT type	Non-use	2,126,753	2,580	Reference
	ET*	159,495	209	0.86 (0.75-1.00)
	<i>ET (Estradiol)*</i>	118,910	137	0.87 (0.73-1.04)
	<i>ET (Estriol)*</i>	40,585	72	0.85 (0.67-1.08)
	Tibolone*	20,043	15	0.72 (0.43-1.20)
	EPT*	91,654	78	0.74 (0.59-0.92)
	Other*	49,010	55	0.88 (0.68-1.15)
Route	Non-use	2,126,753	2,580	Reference
	ET Oral*	57,031	72	0.72 (0.57-0.92)
	ET Vaginal*	89,719	119	0.94 (0.78-1.13)
	ET Transdermal*	7,246	10	1.28 (0.69-2.38)
	EPT Oral*	90,126	78	0.75 (0.60-0.94)
	EPT Transdermal*	1,163	0	-
	Other	74,917	78	0.85 (0.68-1.07)
Oral dose Unit increase	Estrogen 1 mg / day*			0.79 (0.64-0.96)
	Progestin 10 mg / month*			1.02 (0.85-1.23)

Incidence risk ratios (RR) were adjusted for age, number of births, highest level of education, marital status, use of antihypertensives, antidiabetics, statins and thyroid therapy. ET: estrogen only therapy. EPT: combined estrogen-progestin therapy. PY: person-years. CRC: colorectal cancer. CI: confidence interval. *Current use.